Listen as James D. Bowen, MD, and Augusto A. Miravalle, MD, review some of the most significant MS research presented at the 63rd AAN annual meeting, held April 9-16, 2011, in Honolulu, Hawaii. Dr. Bowen provides updates in the areas of pathology, immunology, genetics, testing, imaging, and cognitive dysfunction. Dr. Miravalle summarizes the latest data on current and emerging therapies.
Data from AAN 2011 on emerging MS therapies, including laquinimod, cladribine, alemtuzumab, and more.
Data from AAN 2011 on current MS therapies, including interferon beta, glatiramer acetate, natalizumab, mitoxantrone, and fingolimod.
New research on MS-related cognitive dysfunction from AAN 2011.
Testing, Imaging, Biomarkers, and Predictors
Reports from AAN 2011 on evolving applications of imaging and testing in MS.
Pathophysiology, Immunology, Genetics, Neuropreservation - Part 2
Latest research from AAN 2011 on mechanisms of disease progression in MS.
Pathophysiology, Immunology, Genetics, Neuropreservation - Part 1
Latest research from AAN 2011 on risk factors for and pathogenesis of MS.